Congress Materials
The following information is being provided in response to your specific unsolicited request. Incyte provides information to healthcare professionals to facilitate research and scientific exchange. The information provided is limited to Incyte and Incyte/Novartis co-sponsored trials. Information related to JAKAFI® (ruxolitinib), PEMAZYRE® (pemigatinib), OPZELURA® (ruxolitinib) cream, MONJUVI® (tafasitamab-cxix), NIKTIMVO™ (axatilimab-csfr) or ZYNYZ® (retifanlimab-dlwr) is not intended to offer recommendations for any administration, indication, dosage, or other use inconsistent with the approved Prescribing Information.
The efficacy and safety of the investigational compounds listed have not been established. There is no guarantee that these compounds will become commercially available for the use(s) under investigation.
Results include posters and oral presentations from medical congresses occurring in the past 2 years.